Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4945 - Pre-diagnostic measurements of high-sensitive C - reactive protein and risk of Prostate Cancer. The PROCA-life study

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Einar Stikbakke

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

E. Stikbakke1, H.S. Haugnes2, I. Thune3, T. Wilsgaard4, T. Knutsen5, E.H. Richardsen6

Author affiliations

  • 1 Department Of Clinical Medicine, University of Tromso The Arctic University of Norway, 9037 - Tromso/NO
  • 2 Department Of Oncology, University Hospital of North Norway, 9019 - Tromso/NO
  • 3 Departement Of Clinical Medicine, University of Tromso The Arctic University of Norway, 9037 - Tromso/NO
  • 4 Department Of Community Medicine, University of Tromso The Arctic University of Norway, 9037 - Tromso/NO
  • 5 Department Of Urology, University Hospital of North Norway, 9019 - Tromso/NO
  • 6 Department Of Pathology, University Hospital of North Norway, 9019 - Tromso/NO
More

Resources

Abstract 4945

Background

Inflammation may promote prostate cancer development, which can be characterized by elevated circulating levels of inflammation markers, such as high-sensitivity C-reactive protein (hs-CRP). Whether pre-diagnostic measurements of hs-CRP are associated with prostate cancer remains unknown.

Methods

In the Prostate Cancer Study throughout life (PROCA-life), a total of 11 064 initially healthy men, who participated in the Tromsø Study between 1994 and 2008, were included. Pre-diagnostic hs-CRP was assessed and height and weight were measured at study entry. During a mean follow-up time of 14.2 years, a total of 459 men developed histological verified prostate cancer and detailed medical and histological records were obtained.

Results

At study entry, the cohort participants had a mean age of 60.5, mean level of hs-CRP of 2.18 mg/l and a mean body mass index (BMI) of 25.8 kg/m2. The 459 prostate cancer cases identified had a mean age at diagnosis of 72.0 years. Among normal weighted men (BMI<25kg/m2), we observed a positive linear relationship between pre-diagnostic hs-CRP levels and prostate cancer risk after adjustments, both when using single and repeated measurements of hs-CRP, with hazard ratio 1.09 (95% CI 1.03-1.14) and 1.08 (95% CI 1.01-1.16), respectively. This relationship was not present in the overweight (BMI 25-30 kg/m2) or obese (BMI>30kg/m2) group.

Conclusions

Our study supports the hypothesis that inflammation may play a role in prostate cancer development, but this association may vary by body composition.

Clinical trial identification

Legal entity responsible for the study

University of Tromsø.

Funding

University of Tromsø.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.